Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
14. Dezember 2023 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
Global Kidney Cancer Drugs Market Research Report 2023: Forecasts to 2027 & 2032 with Focus on Axitinib (Inlyta), Cabozantinib (cabometyx), and Pazopanib
13. März 2023 08:53 ET
|
Research and Markets
Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global kidney cancer drugs market will...
Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
09. März 2023 16:05 ET
|
Clearside Biomedical, Inc.
- Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety...
Global Kidney Cancer Drugs Market Report 2022-2026 & 2030 - Focus on Immunotherapy, Chemotherapy and Targeted Therapy
19. April 2022 04:48 ET
|
Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2022, Type, Product, End Users" report has been added to ResearchAndMarkets.com's offering. The global...
Kidney Cancer Drugs Industry Assessment and Recovery to 2030 - Insights on Drugs, Trends, Global Market Shares, Competitors, Strategies and More
04. Februar 2022 04:38 ET
|
Research and Markets
Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. The...
Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
21. September 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX (axitinib injectable suspension) Administered in Suprachoroidal Space
10. August 2020 16:02 ET
|
Clearside Biomedical, Inc.
- Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 - ALPHARETTA, Ga., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a...
Clearside Biomedical Announces Multiple Presentations at the ASRS 2020 Virtual Annual Meeting
27. Juli 2020 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...